Loading...

Purified anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_Pure_071608.jpg
BALB/c splenocytes stained with 30-F11 purified, followed by anti-rat IgG FITC
  • 30-F11_Pure_071608.jpg
    BALB/c splenocytes stained with 30-F11 purified, followed by anti-rat IgG FITC
  • 30-F11_Pure_CD45_Antibody_2_102518
    Fresh, frozen mouse spleen was stained with purified CD45 clone 30-F11 conjugated and detected with a FITC CODEX™ oligonucleotide duplex (red). Samples were counterstained with CollagenIV Cy5 (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Quantity Check Availability Save
103101 50 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103102 500 µg 92€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, CyTOF® - Verified
IP, CMCD, IHC, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed
  2. Claveria-Cabello A, et al. 2020. Cancers (Basel). 12:00. PubMed
  3. Davies M, et al. 2017. PLoS Pathogens. 13(6):e1006435. PubMed
  4. Axelrod HD, et al. 2019. Mol Cancer Res. 17:356. PubMed
  5. Schneider H, et al. 2017. J Neurochem. 140:170. PubMed
  6. Shafer MER, et al. 2017. Stem Cell Reports. 1.040277778. PubMed
  7. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  8. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  9. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  10. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  11. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  12. Tremblay M, et al. 2020. Elife. 9: . PubMed
  13. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  14. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  15. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  16. Moore J, et al. 2022. Cancer Res. 82:365. PubMed
  17. Park JY, et al. 2022. Cell Rep. 38:110219. PubMed
  18. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  19. Lee NK, et al. 2022. Biomedicines. 10: . PubMed
  20. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  21. Li S, et al. 2022. Nat Commun. 13:7371. PubMed
  22. Abby E, et al. 2023. Nat Genet. 55:232. PubMed
  23. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  24. Blomberg E, et al. 2022. Neurooncol Adv. 4:vdac148. PubMed
  25. Murai K, et al. 2022. Nat Commun. 13:6206. PubMed
  26. Tarazi S, et al. 2022. Cell. 185:3290. PubMed
  27. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  28. Wang Y, et al. 2023. J Neuroinflammation. 20:41. PubMed
  29. García Fallit M, et al. 2023. Viruses. 15:. PubMed
  30. Xu J, et al. 2023. Discov Oncol. 14:68. PubMed
  31. Rafaiee R, et al. 2023. Bioimpacts. 13:97. PubMed
  32. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  33. Chamberlin T, et al. 2020. Cancer Research. 80(20):4465-4475. PubMed
  34. Li X, et al. 2020. Cell Rep. 31:107765. PubMed
  35. Vitiello GA, et al. 2018. Clin Cancer Res. 24:972. PubMed
  36. Rothchild AC, et al. 2019. Sci Immunol. 4:eaaw6693. PubMed
  37. Widjaja AA, et al. 2019. Gastroenterology. 157:777. PubMed
  38. Kondo H, et al. 2020. J Biol Chem. 295:1658. PubMed
  39. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
  40. Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed
  41. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  42. Maestro S, et al. 2021. Viruses. 13: . PubMed
  43. Moon H et al. 2017. Cell stem cell. 21(5):665-678 . PubMed
  44. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  45. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  46. Goel S, et al. 2017. Nature. 548:471. PubMed
  47. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  48. Paulo E, et al. 2018. Sci Rep. 8:11001. PubMed
  49. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  50. Heinrich A, et al. 2021. Cell Rep. 37:109885. PubMed
  51. Cooper STE, et al. 2022. Int J Mol Sci. 23:. PubMed
  52. Deppermann C, et al. 2020. J Exp Med. 217:. PubMed
  53. Liu X, et al. 2020. Nature. . PubMed
  54. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  55. Parlanti P, et al. 2020. Exp Eye Res. 194:107998. PubMed
  56. Lee S, et al. 2020. Cell Host & Microbe. 27(6):937-949. PubMed
  57. Thulasingam S, et al. 2019. Int J Mol Sci. 20. PubMed
  58. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  59. Starossom SC, et al. 2019. Nat Commun. 10:217. PubMed
  60. Dertschnig S, et al. 2020. J Clin Invest. 130:1896. PubMed
  61. Gao H, et al. 2021. J Virol. :. PubMed
  62. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  63. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  64. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  65. Zabaleta N, et al. 2018. Nat Commun. 9:5454. PubMed
  66. Zhu F, et al. 2019. J Immunol. 203:2644. PubMed
  67. Li Y et al. 2019. Endocrinology. 160(4):938-946 . PubMed
  68. Murad JP, et al. 2018. Front Immunol. 1.95. PubMed
  69. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  70. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  71. Quintana E, et al. 2020. Cancer Res. 80:2889. PubMed
  72. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  73. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  74. Podd B, et al. 2006. J Immunol. 176:6532. PubMed
  75. Hitchcock JR, et al. 2020. FEBS J. 287:250. PubMed
  76. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  77. Sutton C, et al. 2017. Nat Commun.. 10.1038/s41467-017-02111-0. PubMed
  78. Janghorban M, et al. 2022. Cancer Res. 82:885. PubMed
  79. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  80. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  81. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  82. Baraibar-Churio A, et al. 2021. Life (Basel). 11:. PubMed
  83. Nam J, et al. 2021. Front Cell Neurosci. 15:640084. PubMed
  84. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  85. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
  86. Rhee S, et al. 2018. Nat Commun. 9:368. PubMed
  87. Finn J et al. 2019. Cell reports. 26(11):2942-2954 . PubMed
  88. Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed
  89. Fiege JK, et al. 2019. PLoS Pathog. 15:e1008077. PubMed
  90. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  91. Melchor SJ, et al. 2020. Sci Rep. 10:15724. PubMed
  92. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  93. Baluk P, et al. 2020. Am J Pathol. 190:2355. PubMed
  94. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  95. Gil-Melgosa L, et al. 2021. Biomedicines. 10:. PubMed
  96. Karhadkar TR, et al. 2021. PLoS One. 16:e0245924. PubMed
  97. Gereke M, et al. 2012. J Vis Exp. 70: 4322. PubMed
  98. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  99. Yoshihara S, et al. 2019. Front Immunol. 0.545833333. PubMed
  100. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  101. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  102. Yim AKY, et al. 2022. Nat Neurosci. 25:238. PubMed
  103. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  104. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  105. Fu H, et al. 2020. Front Immunol. 11:595813. PubMed
  106. Peralta Ramos JM, et al. 2017. Front Immunol. 1.490277778. PubMed
  107. Ito S, et al. 2020. PLoS One. 15:e0229888. PubMed
  108. Latasa M, et al. 2010. PLoS One. 5:e15690. PubMed
  109. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  110. Bruno KA, et al. 2021. Int J Mol Sci. 22:. PubMed
  111. Crawford LB, et al. 2020. Microorganisms. 8:. PubMed
  112. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  113. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
  114. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  115. Kenswil KJG, et al. 2021. Cell Stem Cell. 28(4):653-670.e11. PubMed
  116. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  117. Qiu X, et al. 2018. Lab Chip. 18:2776. PubMed
  118. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  119. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  120. Vu LT, et al. 2019. J Extracell Vesicles. 8:1599680. PubMed
  121. Jones KB et al. 2018. Cell stem cell. 24(1):183-192 . PubMed
  122. Zhong L, et al. 2022. JCI Insight. 7:. PubMed
  123. Nikolaou K, et al. 2014. EMBO J. 34:430. PubMed
  124. Murai K et al. 2018. Cell stem cell. 23(5):687-699 . PubMed
  125. Morita S et al. 2017. Cell metabolism. 25(4):883-897 . PubMed
  126. Sheppard S, et al. 2018. Front Immunol. 1.630555556. PubMed
  127. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  128. Paharik AE, et al. 2017. Cell Host Microbe. 22:746. PubMed
  129. Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed
  130. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  131. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  132. Hashimoto M, et al. 2021. J Neurochem. 156:834. PubMed
  133. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  134. Scur M, et al. 2022. Nat Commun. 13:7272. PubMed
  135. Karhadkar TR, et al. 2020. bioRxiv. . PubMed
  136. Chen Q, et al. 2021. STAR Protocols. 2(1):100241. PubMed
  137. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  138. Bar O, et al. 2020. Fluids Barriers CNS. 17:27. PubMed
  139. Langer V, et al. 2019. J Clin Invest. 129:4691. PubMed
  140. Poulos MG, et al. 2017. J Clin Invest. 127:4163. PubMed
  141. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  142. Lopes N, et al. 2021. Nat Immunol. 22:179. PubMed
  143. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  144. Ejima R, et al. 2021. Nutrients. 13:. PubMed
  145. Hu CF, et al. 2021. Front Immunol. 12:638381. PubMed
  146. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  147. Yu W, et al. 2020. J Clin Invest. . PubMed
  148. Baluk P, et al. 2018. Methods Mol Biol. 1846:161. PubMed
  149. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  150. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  151. Geng T, et al. 2021. J Infect Dis. 223:2186. PubMed
  152. Ishigaki K, et al. 2021. Sci Rep. 11:13958. PubMed
  153. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  154. Somasundaram R, et al. 2021. Blood. 137:3037. PubMed
  155. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  156. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
  157. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  158. Moon H, et al. 2019. Nat Commun. 10:2225. PubMed
  159. Wang Z, et al. 2021. Drug Discov Ther. 14:304. PubMed
  160. Levy BD, et al. 2020. J Allergy Clin Immunol. 145:335. PubMed
  161. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  162. Cha J, et al. 2015. J Biol Chem. 290:15337. PubMed
  163. Mori Y, et al. 2021. Diabetes and Vascular Disease Research. 18(3):14791641211027324. PubMed
  164. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  165. Tamburini BAJ, et al. 2019. Front Immunol. 10:1036. PubMed
  166. Dora D, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1617. PubMed
  167. Fahy N, et al. 2021. Front Immunol. 12:715267. PubMed
  168. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  169. Rincón E, et al. 2017. Oncotarget. 8:45415. PubMed
  170. Deng W et al. 2019. Cell reports. 27(6):1755-1768 . PubMed
  171. Van Der Zande HJP, et al. 2021. FASEB J. 35:e21331. PubMed
  172. Penny HL, et al. 2021. Int J Mol Sci. 22:. PubMed
  173. DeFalco T, et al. 2014. Proc Natl Acad Sci U S A. 111:2384. PubMed
  174. Li Y, et al. 2020. Elife. 9:00. PubMed
  175. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  176. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  177. Heinrich A, et al. 2020. Cell Rep. 31:107513. PubMed
  178. Parodi B, et al. 2021. Front Immunol. 12:655212. PubMed
  179. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  180. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  181. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  182. Aikawa S, et al. 2020. Cell Death Differ. 1489:27. PubMed
  183. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  184. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  185. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  186. Stokes KL, et al. 2019. Oncogenesis. 8:24. PubMed
  187. Krenzlin H, et al. 2019. J Clin Invest. 130:1671. PubMed
  188. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  189. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  190. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  191. Maier B, et al. 2020. Nature. 580:257. PubMed
  192. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  193. Kästle M, et al. 2020. Cell Commun Signal. 183:18. PubMed
  194. Bernard S, et al. 2018. J Mammary Gland Biol Neoplasia. 23:249. PubMed
  195. Leist SR, et al. 2019. PLoS One. 14:e0220126. PubMed
  196. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  197. Hassel C, et al. 2021. Front Immunol. 12:754661. PubMed
  198. Obst J, et al. 2020. Front Immunol. 11:579000. PubMed
  199. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  200. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  201. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  202. Haber AL, et al. 2017. Nature. 551:333. PubMed
  203. Emrick JJ, et al. 2018. Proc Natl Acad Sci U S A. 115:E12091. PubMed
  204. Seehus CR, et al. 2017. Nat Commun. 8:1900. PubMed
  205. Cédile O, Wlodarczyk A, and Owens T 2017. APMIS.. 10.1111/apm.12740. PubMed
  206. Wilke JBH, et al. 2021. Mol Psychiatry. 26:7746. PubMed
  207. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  208. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
RRID
AB_312966 (BioLegend Cat. No. 103101)
AB_312966 (BioLegend Cat. No. 103102)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV395™ anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 10.25.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account